Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy

Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy

Source: 
CP Wire
snippet: 
  • Domagrozumab Ph II study did not meet primary endpoint
  • Pfizer is also developing a gene therapy, PF-06939926, for DMD
  • PF-06939926 has orphan status in the US and Europe